查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030285

Ibuprofen市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、應用、地區和競爭對手分類，2021-2031年

Ibuprofen Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球Ibuprofen市場預計將從 2025 年的 5.4711 億美元成長到 2031 年的 7.2858 億美元，複合年成長率為 4.89%。

Ibuprofen是一種領先的非類固醇消炎劑(NSAID)，因其具有解熱、鎮痛和抗發炎作用，被廣泛用於治療疼痛、發燒和發炎。市場成長的主要驅動力是發炎性疾病和慢性疼痛的日益普遍，以及老年人口不斷成長對可靠止痛藥的需求。此外，消費者對價格實惠、易於取得的非處方藥的需求不斷成長，以及學名藥的普及，也對推動該行業發展起到了重要作用。美國藥典 (USP) 在 2024 年指出，印度繼續在美國活性成分 (API) 生產領域佔據主導地位，占美國活性成分主文件 (DMF) 總量的 48%，凸顯了全球 API 生產的集中度。

市場概覽
預測期 2027-2031
市場規模：2025年 5.4711億美元
市場規模：2031年 7.2858億美元
複合年成長率：2026-2031年 4.89%
成長最快的細分市場 藥片
最大的市場 北美洲

限制該市場成長的主要障礙在於全球Ibuprofen供應鏈的根本脆弱性。該供應鏈嚴重依賴數量有限的活性藥物成分（API）生產商。這種高度集中化使得該行業極易受到地緣政治緊張局勢和突發全球危機造成的供應中斷影響，進而可能對產品的穩定供應產生負面影響。

市場促進因素

發炎性疾病和慢性疼痛發生率的上升是推動Ibuprofen等止痛藥需求成長的主要動力。隨著偏頭痛、關節炎和各種肌肉骨骼疾病等健康問題在全球範圍內持續增加，對可靠且易於獲得的疼痛治療方法的需求比以往任何時候都更加迫切。許多人面臨持續性疼痛，嚴重影響了他們的生活品質，導致他們更加依賴藥物來緩解症狀。由於Ibuprofen在緩解疼痛和腫脹方面已被證實有效，因此它仍然是治療短期和長期症狀的主要選擇。世界衛生組織 (WHO) 在 2024 年 1 月舉辦的網路研討會凸顯了這一巨大的醫療保健挑戰，該研討會指出，全球約有 17.1 億人患有肌肉骨骼疾病，其中腰痛是導致殘疾的主要原因之一。這保證了對治療性介入的持續需求。

消費者對非處方藥（OTC）日益成長的偏好是推動國際Ibuprofen自我治療發展的另一個主要動力。人們越來越傾向於自行用藥，他們欣賞非處方藥的便利性和即時性，這些藥物可以用於治療輕微疾病和日常疼痛，無需醫生處方箋。健康意識的提高和對經濟實惠的治療方法的需求進一步推動了這一趨勢。零售商店和藥局中各種形式的Ibuprofen的便利供應與這些消費者的習慣完美契合。歐洲自我護理產業協會（AESGP）2024年度報告（該報告在2025年7月的一份文件中被引用）顯示，前一年用於自我用藥的非處方藥銷量高達47億盒，凸顯了非處方藥產業的快速成長。此外，印度製藥製造商協會 (IPA) 在 2024 年報告稱，印度 2023-2024 會計年度的藥品出口額達到約 278.4 億美元，凸顯了關鍵地區在國際藥品供應網路（包括活性成分的供應）中發揮的關鍵作用。

市場挑戰

全球Ibuprofen市場發展面臨的一大障礙是其供應鏈的根本不穩定性。這項弱點主要源自於對少數活性成分（API）供應商的過度依賴。由於這種地理集中，主要產區的任何中斷，無論是自然災害、地緣政治緊張局勢還是突發的全球危機，都可能嚴重影響IbuprofenAPI的穩定供應。

這些潛在的供應中斷往往會導致原料短缺，延誤終端製藥廠商的生產計劃，進而限制該產業滿足國際需求的能力。美國藥典（USP）在2024年發布的報告凸顯了這個問題，報告顯示中國擁有全球18%的活性成分（API）藥品主文件，顯示全球大部分API生產集中在少數幾個地區。這種對有限供應商的過度依賴必然會增加價格波動和交貨延遲的風險，威脅供應可靠性，並直接阻礙全球Ibuprofen市場的整體成長。

市場趨勢

國際Ibuprofen市場正經歷一場重大變革，其主要驅動力是線上藥局和數位零售平台的快速擴張。這些平台從根本上改變了患者尋找和購買藥品的方式。這一趨勢透過提高購買便利性和擴大Ibuprofen產品的種類，使消費者更容易進行自我用藥。藥品自我治療向數位轉型，實現了直接送貨上門和提供詳細的產品信息，顯著擴大了行業的客戶群體，尤其是非處方Ibuprofen產品。根據歐洲電子藥局協會預測，到2024年，歐洲13個主要線上藥局市場的總合銷售額將達到120億歐元，凸顯了這些數位供應鏈管道的快速成長及其重要的經濟意義。

第二個重要趨勢是高效率速效Ibuprofen製劑的持續研發。製藥公司正積極投資研發，致力於開發能夠更快緩解疼痛並提供更佳用戶體驗的產品。這些技術突破不僅直接滿足了尋求即時緩解症狀人群的需求，也幫助品牌在競爭激烈的市場中脫穎而出。諸如液體凝膠、微粉化片劑和懸浮液等創新產品，均經過專門設計，旨在加速藥物吸收，確保更高的生物利用度。這種對創新的執著追求，正在加速新產品的研發，並拓展Ibuprofen的實際應用範圍，以滿足不同消費者的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球Ibuprofen市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（片劑、膠囊、糖漿、注射）
    • 依用途分類（類風濕性關節炎、僵直性脊椎炎、發炎性疾病、月經、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美Ibuprofen市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲Ibuprofen市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區Ibuprofen市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲Ibuprofen市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲Ibuprofen市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球Ibuprofen市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Pfizer Inc.
  • Abbott Laboratories Inc.
  • Gilead Sciences Inc.
  • Merck KGaA
  • Astellas Pharma Inc.
  • Glenmark Pharmaceuticals Ltd.
  • NATCO Pharma Ltd.
  • Basilea Pharmaceutical AG
  • Leadiant Biosciences Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 7235

The Global ibuprofen market is anticipated to expand from USD 547.11 Million in 2025 to USD 728.58 Million by 2031, reflecting a compound annual growth rate (CAGR) of 4.89%. As a prominent nonsteroidal anti-inflammatory drug (NSAID), ibuprofen is extensively used to treat pain, fever, and inflammation due to its antipyretic, analgesic, and anti-inflammatory effects. This market growth is largely fueled by the rising frequency of inflammatory disorders and chronic pain, alongside an expanding elderly demographic in need of dependable pain relief. Furthermore, the surging need for cost-effective, readily available over-the-counter drugs and the proliferation of generic alternatives play a crucial role in propelling the industry forward. The United States Pharmacopeia (USP) noted in 2024 that India continued to dominate the Active Pharmaceutical Ingredient (API) manufacturing sector for U.S. medicines, accounting for 48% of all active API Drug Master Files (DMFs) and highlighting the centralization of worldwide API manufacturing.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 547.11 Million
Market Size 2031USD 728.58 Million
CAGR 2026-20314.89%
Fastest Growing SegmentTablet
Largest MarketNorth America

A major hurdle hindering the growth of this market is the fundamental fragility of the worldwide ibuprofen supply chain, which heavily depends on a restricted group of Active Pharmaceutical Ingredient producers. This high level of centralization leaves the industry susceptible to supply interruptions caused by geopolitical tensions or unexpected global crises, which can negatively affect the steady availability of the product.

Market Driver

The escalating rate of inflammatory diseases and chronic pain is a primary catalyst for the demand for pain relievers such as ibuprofen. With the worldwide occurrence of health issues like migraines, arthritis, and diverse musculoskeletal disorders steadily climbing, the need for reliable and easily obtainable pain therapies is greater than ever. A large number of people face ongoing pain that drastically lowers their standard of living, resulting in a heavier dependence on symptom-relieving medications. Because of its proven ability to mitigate pain and swelling, ibuprofen remains a top option for treating both short-term and long-term conditions. Highlighting this immense healthcare challenge, a January 2024 World Health Organization webinar revealed that roughly 1.71 billion individuals globally endure musculoskeletal disorders, with lower back pain acting as a primary driver of disability, ensuring a continuous need for therapeutic interventions.

The growing inclination of consumers toward over-the-counter (OTC) medications acts as another major growth engine for the international ibuprofen industry. People are progressively turning to self-medication for minor illnesses and everyday aches, appreciating the ease and instant accessibility of OTC options that bypass the need for doctor prescriptions. Enhanced health awareness and a push for budget-friendly treatment alternatives further strengthen this movement. The seamless availability of different ibuprofen formats in retail shops and pharmacies perfectly aligns with these consumer habits. Data from the Association of the European Self-Care Industry (AESGP), cited in a July 2025 reference to its 2024 annual report, showed that 4.7 billion non-prescription medicine packages were purchased for self-management over the previous year, highlighting a booming non-prescription sector. Additionally, the Indian Pharmaceutical Alliance (IPA) reported in 2024 that India's pharmaceutical exports hit roughly USD 27.84 billion during the 2023-2024 fiscal cycle, showcasing the critical role of major regions in the international drug supply network, including the provision of active pharmaceutical ingredients.

Market Challenge

A prominent obstacle hindering the advancement of the worldwide ibuprofen market is the fundamental instability of its supply network. This weakness is primarily caused by an intense dependence on a very small group of providers for Active Pharmaceutical Ingredients. Because of this geographic centralization, any disturbances in vital production areas-whether stemming from natural catastrophes, geopolitical tensions, or unexpected worldwide crises-can drastically compromise the steady flow of ibuprofen API.

These potential interruptions frequently result in material shortages that delay the manufacturing timelines of final drug producers, thereby restricting the industry's ability to fulfill international demand. Highlighting this issue, the United States Pharmacopeia (USP) reported in 2024 that China held 18% of all active API Drug Master Files, illustrating how a massive share of worldwide API production is localized in just a handful of regions. Relying so heavily on a limited supplier base inherently creates higher chances of price fluctuations and prolonged delivery schedules, which directly restricts the broader growth of the global ibuprofen sector by threatening overall supply reliability.

Market Trends

The international ibuprofen sector is experiencing a major shift driven by the rapid expansion of e-pharmacies and digital retail platforms, which are completely transforming the way patients find and buy their medications. This trend provides greater shopping convenience and a wider array of ibuprofen variations, granting buyers more straightforward access to self-medication strategies. The shift toward digital pharmaceutical distribution enables direct home deliveries and detailed product information, significantly broadening the industry's audience, especially for over-the-counter ibuprofen types. According to the European Association of E-Pharmacies, in 2024, the leading 13 e-pharmacy markets in Europe produced a combined EUR 12 billion in revenue, emphasizing the rapid growth and economic significance of these digital supply channels.

A second crucial development is the continuous creation of highly advanced, fast-acting ibuprofen formulations. Pharmaceutical manufacturers are actively channeling funds into research and development to engineer products that deliver faster pain reduction and a better overall user experience. These technological leaps directly address the public's desire for immediate symptom relief while helping brands stand out in a fiercely contested market. Breakthroughs such as liquid gels, micronized tablets, and suspension formulas are specifically designed to ensure quicker bodily absorption and superior bioavailability. This dedication to innovation accelerates new product development and broadens the practical applications of ibuprofen to meet diverse consumer requirements.

Key Market Players

  • Novartis AG
  • Pfizer Inc.
  • Abbott Laboratories Inc.
  • Gilead Sciences Inc.
  • Merck KGaA
  • Astellas Pharma Inc.
  • Glenmark Pharmaceuticals Ltd.
  • NATCO Pharma Ltd.
  • Basilea Pharmaceutical AG
  • Leadiant Biosciences Inc.

Report Scope

In this report, the Global Ibuprofen Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ibuprofen Market, By Product Type

  • Tablet
  • Capsule
  • Syrup
  • Injection

Ibuprofen Market, By Application

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Inflammatory Diseases
  • Dysmenorrhea
  • Others

Ibuprofen Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ibuprofen Market.

Available Customizations:

Global Ibuprofen Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ibuprofen Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Tablet, Capsule, Syrup, Injection)
    • 5.2.2. By Application (Rheumatoid Arthritis, Ankylosing Spondylitis, Inflammatory Diseases, Dysmenorrhea, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Ibuprofen Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Ibuprofen Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Ibuprofen Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Ibuprofen Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application

7. Europe Ibuprofen Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Ibuprofen Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Ibuprofen Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Ibuprofen Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Ibuprofen Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Ibuprofen Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Ibuprofen Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Ibuprofen Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Ibuprofen Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Ibuprofen Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Ibuprofen Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Ibuprofen Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Ibuprofen Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Ibuprofen Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Ibuprofen Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Ibuprofen Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application

10. South America Ibuprofen Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Ibuprofen Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Ibuprofen Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Ibuprofen Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Ibuprofen Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Abbott Laboratories Inc.
  • 15.4. Gilead Sciences Inc.
  • 15.5. Merck KGaA
  • 15.6. Astellas Pharma Inc.
  • 15.7. Glenmark Pharmaceuticals Ltd.
  • 15.8. NATCO Pharma Ltd.
  • 15.9. Basilea Pharmaceutical AG
  • 15.10. Leadiant Biosciences Inc.

16. Strategic Recommendations

17. About Us & Disclaimer